ArticleIntegrative cancer therapies
Biobran/MGN-3, Arabinoxylan Rice Bran, Ameliorates the Liver Architecture in Ehrlich Ascites Tumor-Bearing Mice as a Cotreatment with Chemotherapy.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancement of Anti-Neoplastic Effects of MGN-3/Biobran Against Solid Ehrlich Carcinoma-Bearing Mice via Lipidic Nanoparticle Based Targeted Drug Delivery System.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic metastases are a leading cause of mortality in gastrointestinal cancers, often exacerbated by the limited efficacy of conventional chemotherapeutics. Biobran/MGN-3, a rice bran-derived arabinoxylan, has shown promise in sensitizing cancer cells to paclitaxel.
objectiveThis study evaluates the hepatoprotective potential of Biobran/MGN-3 in a murine model of Ehrlich ascites carcinoma (EAC).
methodsFemale Swiss mice inoculated with EAC were treated with paclitaxel (10 mg/kg) and Biobran (40 mg/kg) concomitantly for 30 days. Tumor volume along with liver function enzymes were quantified, and hepatic tissue was examined using Masson's trichrome staining, histopathology, and transmission electron microscopy.
resultsBiobran administration significantly reduced tumor volume and liver enzyme levels, indicating improved hepatic function. Collagen deposition around hepatic capillaries was markedly diminished. Histological analysis revealed restoration of normal lobular architecture, while ultrastructural examination showed enhanced nuclear integrity, bile duct morphology, and cytoplasmic organelle preservation. Notably, Biobran activated Kupffer cells to target neoplastic cells infiltrating hepatic parenchyma.
conclusionBiobran/MGN-3, in combination with paclitaxel, confers substantial hepatoprotective effects in EAC-bearing mice, supporting its potential as a nutraceutical adjunct in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.